ArticleAmerican journal of cancer research2017
miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2.
Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 71 citations in OpenAlex.
- Fisetin Modulates Chemoresistance-Associated miR-21, miR-181a, miR-203, miR-101 and miR-381 in Capecitabine-Resistant HT29 Colorectal Cancer Cells.Biochemical genetics · 2026Article
- Article
- DLK1-DIO3 region as a source of tumor suppressor miRNAs in papillary thyroid carcinoma.Translational oncology · 2024Article
- UBE2C: A pan-cancer diagnostic and prognostic biomarker revealed through bioinformatics analysis.Cancer reports (Hoboken, N.J.) · 2024Article
- Tumor-suppressing effects of miR-381-3p in pediatric acute myeloid leukemia via ROCK1 downregulation.Functional & integrative genomics · 2023Article
- Long non-coding RNA FLVCR1-AS1 functions as a ceRNA to aggravate cervical cancer cell growth by the miR-381-3p/MAGT1 axis.Archives of gynecology and obstetrics · 2022Article
- Article
- CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.Cancer cell international · 2022Article
- MicroRNA-381 in human cancer: Its involvement in tumour biology and clinical applications potential.Journal of cellular and molecular medicine · 2022Review
- miR-381 Inhibits Proliferation and Invasion of Non-Small-Cell Cancer Cells by Targeting USP39.Disease markers · 2022Article
- Article
- miR-381-3p suppresses breast cancer progression by inhibition of epithelial-mesenchymal transition.World journal of surgical oncology · 2021Article
- MicroRNAs as Modulators of Oral Tumorigenesis-A Focused Review.International journal of molecular sciences · 2021Review
- Salivary Micro-RNA and Oral Squamous Cell Carcinoma: A Systematic Review.Journal of personalized medicine · 2021Review
- Long Non-Coding RNA LINC01569 Promotes Proliferation and Metastasis in Colorectal Cancer by miR-381-3p/RAP2A Axis.Frontiers in oncology · 2021Article
- The LncRNA CASC11 Promotes Colorectal Cancer Cell Proliferation and Migration by Adsorbing miR-646 and miR-381-3p to Upregulate Their Target RAB11FIP2.Frontiers in oncology · 2021Article
- NRP2, a potential biomarker for oral squamous cell carcinoma.American journal of translational research · 2021Article
- miR-381-3p Involves in Glioma Progression by Suppressing Tumor-Promoter Factor ANTXR1.Computational and mathematical methods in medicine · 2021Article
- Review
- Noncoding RNAs in oral premalignant disorders and oral squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutiple microRNAs are implicated in oral squamous cell carcinoma (OSCC), which is characterized by a high rate of proliferation and nodal metastasis. Data from the present study showed that miR-381-3p is significantly underexpressed in both OSCC tissues and cell lines. Overexpression of miR-381-3p led to marked suppression of proliferation and cell cycle progression of OSCC cells and promotion of apoptosis. Notably, fibroblast growth factor receptor 2 (FGFR2) was downregulated by miR-381-3p through direct interactions with its 3' untranslated region. Knockdown of FGFR2 recapitulated the growth suppressive effect of miR-381-3p. Conversely, restoring FGFR2 expression attenuated miR-381-3p-induced effects in OSCC cells. Expression patterns of miR-381-3p and FGFR2 were inversely correlated in OSCC tissues. Our collective results provide novel evidence that miR-381-3p acts as a tumor suppressor in OSCC by directly targeting FGFR2, thereby presenting a promising therapeutic target.
Indexed as
Identifiers
28469963PMC5411798W2980370904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.